Register Study of the Neoadjuvanten Treatment by Patients With Rectumcarcinoma
NCT ID: NCT03428867
Last Updated: 2018-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
78 participants
OBSERVATIONAL
2012-08-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hyperthermia With Chemoradiotherapy in Rectal Cancer
NCT06831981
Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer
NCT02353858
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
NCT01716949
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
NCT03561142
Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
NCT07337876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chemotherapy:
neoadjuvant= day 1-5 and day 29-33 5FU 1000mg/m2 adjuvant = 4 Cycles 5FU 500mg/m2 all 4 weeks
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. med. Daniel Zips
Prof.Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Zips, Prof.Dr.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tuebingen
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UKT_RO_HT_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.